Home › Neurologic Diseases › Florida › West Palm Beach
Neurologic Diseases clinical trials in West Palm Beach, FL
4 studies for Neurologic Diseases are looking for participants at sites in and around West Palm Beach (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
RecruitingPhase 2
- Clinical Site, West Palm Beach
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
RecruitingPhase 2
- Palm Beach Neurology, West Palm Beach
- JEM Research Institute, Atlantis · 9 mi away
A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic Therapy
RecruitingPhase 2
- Vima Site #053, Palm Beach · 1 mi away
A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
RecruitingPhase 2
- Clinical Site, West Palm Beach
About Neurologic Diseases
Your nervous system includes your brain, spinal cord, and nerves. Learn about neurologic diseases, including their symptoms, causes, and treatments.
More about Neurologic Diseases on MedlinePlus
Neurologic Diseases trials in other cities
- Boston, MA10 studies
- Washington, DC8 studies
- Miami, FL7 studies
- Philadelphia, PA7 studies
- Orlando, FL7 studies
- Dallas, TX7 studies
- St. Louis, MO6 studies
- Houston, TX6 studies
- San Diego, CA6 studies
- New York City, NY6 studies
- Chicago, IL6 studies
- Pittsburgh, PA5 studies
Other studies in West Palm Beach
- Alzheimer's Disease13 studies
- Non-Small Cell Lung Cancer13 studies
- Ovarian Cancer11 studies
- Obesity10 studies
- Overweight9 studies
- Endometrial Cancer8 studies
- Heart Failure7 studies
- Major Depressive Disorder7 studies
- Schizophrenia7 studies
- Cardiovascular Disease7 studies
- COPD6 studies
- HIV6 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.